Skip to the main content.
Other Therapy Areas

Extending our scientific depth across allergy, dermatology, ophthalmology, respiratory, women's health, and more.

Learn More →

News and Press Releases

Read Veristat news and press releases to learn about our CRO service growth, geographic expansion in Europe and Asia, biotechnology preferred partnerships and small CRO acquisitions.

Why Submission Bottlenecks Matter

The period between database lock and regulatory submission is often one of the most time-sensitive...

Veristat Cuts Biostat Analysis Time for Clene Nanomedicine

Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New...

Veristat Helps Impact Therapeutics Receive a Positive CHMP Opinion for Sepalna

Veristat Helps Impact Therapeutics Receive CHMP Marketing Authorization for Sepalna

Veristat Expands Biostatistics Leadership to Accelerate AI-Powered Drug Development in Complex Disease Areas

Veristat deepens expertise with Dr. Zhaohui Su and Dr. Gil Fine, names Scott Tarrant EVP of Drug...

Veristat Launches AI Biostatistics Platform: Cutting Clinical Trial Data Readout Time from Weeks to Days* Without Regulatory Risks

InStat™ delivers submission-ready tables, lists and figures (TLF) on validated statistical...

Veristat Acquires Certara's Regulatory and Medical Writing Business

Veristat Expands Regulatory and Medical Writing Capabilities Through Acquisition of Certara’s...

Veristat to Acquire Certara's Regulatory and Medical Writing Business

Strategic acquisition expands and enhances Veristat’s regulatory services to help more clinical...

Veristat Expands Regulatory and Clinical Services to Chinese Drug and Device Companies Seeking Efficient Way to Enter European Markets

International companies find a new, frictionless path to secure regional approvals in Veristat

Veristat Names Industry Veteran Kim McLean Boericke as 
New Chief Executive Officer

Boericke succeeds Patrick Flanagan, who is transitioning to the Board of Directors

Southborough, MA...

Cook MyoSite and Veristat Partner in Complex, Phase III, Adaptive Clinical Study of Investigational Cell Therapy for Unmet Need in Women’s Health

Veristat partners to achieve key enrollment milestone for study; activated 26 sites and enrolled...

Veristat Achieves EcoVadis Committed Badge: A Milestone in Our Sustainability Journey

We're proud to announce that Veristat has received our first EcoVadis Committed Badge, marking a...